Results 21 to 30 of about 14,471,607 (152)

Prothrombin induced by vitamin K absence or antagonist-II (PIVKA-II) predicts complete responses of transarterial chemoembolization for hepatocellular carcinoma

Journal of the Formosan Medical Association, 2022
Background/purpose: Prothrombin Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) is a diagnostic marker for hepatocellular carcinoma (HCC). Transarterial chemoembolization (TACE) is the standard management for intermediate stage HCC but lacks ...
Sung-Yin Wang, Tung-Hung Su, Bang-bin Chen, Chun-Jen Liu, Chen-Hua Liu, Hung-Chih Yang, Tai-Chung Tseng, Pei-Jer Chen, Jia-Horng Kao   +8 more
doaj   +1 more source

Predictors of Complete Response in Patients with Hepatocellular Carcinoma Treated with Trans-Arterial Radioembolization

Current Oncology, 2021
Background: Trans-arterial radioembolization (TARE) has shown promising results in treating hepatocellular carcinoma (HCC). We identified independent predictors of radiological complete response (CR) in patients with intrahepatic HCC who were treated ...
Yuna Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim   +7 more
doaj   +1 more source

HepaClear, a blood-based panel combining novel methylated CpG sites and protein markers, for the detection of early-stage hepatocellular carcinoma

Clinical Epigenetics, 2023
Background Early screening and detection of hepatocellular carcinoma (HCC) can efficiently improve patient prognosis. We aimed to identify a series of hypermethylated DNA markers and develop a blood-based HCC diagnosis panel containing DNA methylation ...
Yi Bai, Juan Xu, Deqiang Li, Xiaoyu Zhang, Dapeng Chen, Fucun Xie, Longmei Huang, Xiaotian Yu, Haitao Zhao, Yamin Zhang   +9 more
doaj   +1 more source

Challenges in the Diagnosis of Hepatocellular Carcinoma in a 32-Year-Old Male With Hepatitis B and Alcohol Use. [PDF]

Clin Case Rep
ABSTRACT Hepatitis B induced hepatocellular carcinoma (HCC) is an important cause of morbidity and mortality in sub‐Saharan Africa and particularly in Zambia presenting at a younger age compared to other regions globally and with poorer prognosis.
Syabbalo E, Mwanza N, Kaoma D, Shumbwa C, Chibuta P, Mulopwe J, Mupeta S, Mubbunu M, Sinkala E.   +8 more
europepmc   +2 more sources

Validation of a novel model for the early detection of hepatocellular carcinoma

Clinical Proteomics, 2019
Background The biomarkers alpha-fetoprotein (AFP) and protein induced by vitamin K absence/antagonist-II (PIVKA-II) may be useful for detecting early-stage hepatocellular carcinoma (HCC). We evaluated the performance of AFP and PIVKA-II levels, alone and
Philip M. Hemken, Lori J. Sokoll, Xiaoqing Yang, Jianliang Dai, Debra Elliott, Susan H. Gawel, Michael Lucht, Ziding Feng, Jorge A. Marrero, Sudhir Srivastava, Daniel W. Chan, Gerard J. Davis   +11 more
doaj   +1 more source

Evaluation of serum AFP and DCP levels in the diagnosis of early-stage HBV-related HCC under different backgrounds

Journal of International Medical Research, 2020
Objective This study compared the diagnostic performance of alpha-fetoprotein (AFP) and des-gamma-carboxyprothrombin (DCP) in early-stage hepatitis B virus-related hepatocellular carcinoma (HBV-HCC) under different backgrounds.
Ting Song, Lili Wang, Ruopei Xin, Liping Zhang, Yun Tian   +4 more
doaj   +1 more source

Proteomic Profiling and Artificial Intelligence for Hepatocellular Carcinoma Translational Medicine

Biomedicines, 2021
Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver with high morbidity and mortality rates worldwide. Since 1963, when alpha-fetoprotein (AFP) was discovered as a first HCC serum biomarker, several other protein biomarkers have
Nurbubu T. Moldogazieva, Innokenty M. Mokhosoev, Sergey P. Zavadskiy, Alexander A. Terentiev   +3 more
doaj   +1 more source

Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child-Pugh Class B. [PDF]

Liver Int
ABSTRACT Background & Aims Despite the advances in systemic therapy for unresectable hepatocellular carcinoma (HCC), patients with Child–Pugh class B (CP‐B) liver function face a significant unmet need. This study evaluated the efficacy and safety of atezolizumab plus bevacizumab (Atez/Bev) in patients with unresectable HCC and CP‐B.
Sasaki R, Shimose S, Saeki I, Ito T, Takeuchi Y, Tani J, Tomonari T, Sasaki K, Kakizaki S, Hatanaka T, Miuma S, Shirono T, Iwamoto H, Tanabe N, Yamamoto T, Kanayama Y, Naganuma A, Nishina S, Takayama T, Kobara H, Otsuka M, Kawashima H, Takami T, Kawaguchi T, Miyaaki H, Hepatology InVestigator Experts in Japan (HIVE‐J) Study Group.   +25 more
europepmc   +2 more sources

ARID1A Deficiency Is Associated With High Programmed Death Ligand 1 Expression in Hepatocellular Carcinoma

Hepatology Communications, 2021
The clinicopathological features of carcinomas expressing AT‐rich interaction domain 1a (ARID1A) and programmed death ligand 1 (PD‐L1) in HCC are poorly understood.
Norifumi Iseda, Shinji Itoh, Tomoharu Yoshizumi, Kyohei Yugawa, Akinari Morinaga, Takahiro Tomiyama, Takeo Toshima, Kenichi Kohashi, Yoshinao Oda, Masaki Mori   +9 more
doaj   +1 more source

Diagnostic utility of alpha‑fetoprotein and des‑gamma‑carboxyprothrombin in Nigerians with hepatocellular carcinoma [PDF]

, 2018
Background: Alpha-fetoprotein (AFP) and Des-gamma-carboxyprothrombin (DCP) have been extensively studied as biomarkers for the diagnosis of and prognostication in hepatocellular carcinoma (HCC).
Adekanle, O., Ette, Akpakip Ikpong, Ndububa, D.A., Ekrikpo, U.   +3 more
core   +1 more source